Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Niagen Bioscience (NASDAQ: NAGE ) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Niagen Bioscience Inc. reported
Arvinas (NASDAQ: ARVN ) reported second-quarter financial results on Tuesday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcripts and financial data. Visit to learn more. Access the full call at Summary Arvinas Inc. reported
Rev $2.74B (est $2.47B) -Leqembi Rev $184M (est $186.4M) -Multiple Sclerosis Rev $963M (est $902.2M) -Adj EPS $3.60 (est $2.89) -Product Rev. $1.92B (est $1.77B) -Now Sees Yr Rev Increase By Mid-Single Digit Percentage -Sees FY Adj EPS $12 To $13, Saw $14.25 To $15.25 -Yr View Updated To Reflect Acquisition-Related Cos
Biogen Inc. (Biogen) expects that its GAAP and non-GAAP results for the second quarter of 2026 will include acquired in-process research and development, upfront and milestone expense of approximately $164 million on a pre-tax basis. The estimated charge is expected to impact GAAP and non-GAAP net income per diluted sh